News >

Neoadjuvant Imatinib Associated With High Rate of R0 Resection in Large Gastric GIST

Jason Harris
Published: Wednesday, Jun 07, 2017

Yukinori Kurokawa, MD, PhD

Yukinori Kurokawa, MD, PhD

Investigators conducting a small multinational study in Asian patients have concluded that 6 to 9 months of treatment with neoadjuvant imatinib (Gleevec) is a promising treatment for patients with large gastric gastrointestinal stromal tumors (GIST).

“It does help support what we’re already doing clinically. Many of us are doing neoadjuvant treatment in patients who have tumors that are large or are in difficult locations,” Keedy said. “It also shows us that it’s safe. None of the patients had perforations; very few patients had progression while on-treatment.”
Kurokawa Y, Yang H, Cho H, et al. Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach [published online May 23, 2017]. Br J Cancer. doi:10.1038/bjc.2017.144.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x